Iovance Biotherapeutics, Inc.
Get $10 bonus on your first $100 deposit for IOVA
Get $10 bonus on your first $100 deposit for IOVA
Iovance Biotherapeutics, Inc. (IOVA) Stock Competitors & Peer Comparison
See (IOVA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IOVA | $3.35 | -3.04% | 1.1B | -3.15 | -$1.09 | N/A |
| VRTX | $434.46 | -2.86% | 111.4B | 28.66 | $15.31 | N/A |
| REGN | $761.83 | -1.98% | 79.2B | 18.36 | $41.49 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $749.04 | +0.80% | 46.2B | 38.20 | $19.54 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $330.80 | +0.63% | 42.3B | 136.85 | $2.33 | N/A |
| INSM | $163.96 | -0.54% | 35B | -25.34 | -$6.41 | N/A |
| UTHR | $555.03 | -2.67% | 24.8B | 20.27 | $27.86 | N/A |
| BNTX | $90.98 | +1.74% | 22.9B | -16.76 | -$5.44 | N/A |
Stock Comparison
IOVA vs VRTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, VRTX has a market cap of 111.4B. Regarding current trading prices, IOVA is priced at $3.35, while VRTX trades at $434.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas VRTX's P/E ratio is 28.66. In terms of profitability, IOVA's ROE is -0.55%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, IOVA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check VRTX's competition here
IOVA vs REGN Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, REGN has a market cap of 79.2B. Regarding current trading prices, IOVA is priced at $3.35, while REGN trades at $761.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas REGN's P/E ratio is 18.36. In terms of profitability, IOVA's ROE is -0.55%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IOVA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check REGN's competition here
IOVA vs VRNA Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IOVA is priced at $3.35, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IOVA's ROE is -0.55%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, IOVA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check VRNA's competition here
IOVA vs ARGX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ARGX has a market cap of 46.2B. Regarding current trading prices, IOVA is priced at $3.35, while ARGX trades at $749.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ARGX's P/E ratio is 38.20. In terms of profitability, IOVA's ROE is -0.55%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, IOVA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ARGX's competition here
IOVA vs SGEN Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IOVA is priced at $3.35, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IOVA's ROE is -0.55%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IOVA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SGEN's competition here
IOVA vs ALNY Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ALNY has a market cap of 42.3B. Regarding current trading prices, IOVA is priced at $3.35, while ALNY trades at $330.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ALNY's P/E ratio is 136.85. In terms of profitability, IOVA's ROE is -0.55%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, IOVA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check ALNY's competition here
IOVA vs INSM Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, INSM has a market cap of 35B. Regarding current trading prices, IOVA is priced at $3.35, while INSM trades at $163.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas INSM's P/E ratio is -25.34. In terms of profitability, IOVA's ROE is -0.55%, compared to INSM's ROE of -1.68%. Regarding short-term risk, IOVA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check INSM's competition here
IOVA vs UTHR Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, UTHR has a market cap of 24.8B. Regarding current trading prices, IOVA is priced at $3.35, while UTHR trades at $555.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas UTHR's P/E ratio is 20.27. In terms of profitability, IOVA's ROE is -0.55%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IOVA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check UTHR's competition here
IOVA vs BNTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, IOVA is priced at $3.35, while BNTX trades at $90.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas BNTX's P/E ratio is -16.76. In terms of profitability, IOVA's ROE is -0.55%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, IOVA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BNTX's competition here
IOVA vs RPRX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, RPRX has a market cap of 20.8B. Regarding current trading prices, IOVA is priced at $3.35, while RPRX trades at $47.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas RPRX's P/E ratio is 27.29. In terms of profitability, IOVA's ROE is -0.55%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, IOVA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RPRX's competition here
IOVA vs ROIV Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ROIV has a market cap of 20.3B. Regarding current trading prices, IOVA is priced at $3.35, while ROIV trades at $27.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ROIV's P/E ratio is -24.21. In terms of profitability, IOVA's ROE is -0.55%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, IOVA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ROIV's competition here
IOVA vs BGNE Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IOVA is priced at $3.35, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IOVA's ROE is -0.55%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, IOVA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BGNE's competition here
IOVA vs RVMD Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, RVMD has a market cap of 19.6B. Regarding current trading prices, IOVA is priced at $3.35, while RVMD trades at $96.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas RVMD's P/E ratio is -16.66. In terms of profitability, IOVA's ROE is -0.55%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, IOVA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RVMD's competition here
IOVA vs MRNA Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, MRNA has a market cap of 19.4B. Regarding current trading prices, IOVA is priced at $3.35, while MRNA trades at $48.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas MRNA's P/E ratio is -6.78. In terms of profitability, IOVA's ROE is -0.55%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, IOVA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MRNA's competition here
IOVA vs INCY Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, IOVA is priced at $3.35, while INCY trades at $94.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas INCY's P/E ratio is 14.97. In terms of profitability, IOVA's ROE is -0.55%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IOVA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check INCY's competition here
IOVA vs DNA-WT Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IOVA is priced at $3.35, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IOVA's ROE is -0.55%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, IOVA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check DNA-WT's competition here
IOVA vs GMAB Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, GMAB has a market cap of 16.9B. Regarding current trading prices, IOVA is priced at $3.35, while GMAB trades at $27.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas GMAB's P/E ratio is 17.86. In terms of profitability, IOVA's ROE is -0.55%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check GMAB's competition here
IOVA vs SMMT Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, SMMT has a market cap of 14.4B. Regarding current trading prices, IOVA is priced at $3.35, while SMMT trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas SMMT's P/E ratio is -13.46. In terms of profitability, IOVA's ROE is -0.55%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, IOVA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SMMT's competition here
IOVA vs BBIO Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, IOVA is priced at $3.35, while BBIO trades at $72.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas BBIO's P/E ratio is -19.35. In terms of profitability, IOVA's ROE is -0.55%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, IOVA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BBIO's competition here
IOVA vs ASND Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ASND has a market cap of 14.1B. Regarding current trading prices, IOVA is priced at $3.35, while ASND trades at $227.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ASND's P/E ratio is -52.58. In terms of profitability, IOVA's ROE is -0.55%, compared to ASND's ROE of +1.28%. Regarding short-term risk, IOVA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ASND's competition here
IOVA vs KRTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IOVA is priced at $3.35, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IOVA's ROE is -0.55%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IOVA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check KRTX's competition here
IOVA vs MDGL Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, IOVA is priced at $3.35, while MDGL trades at $540.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas MDGL's P/E ratio is -42.56. In terms of profitability, IOVA's ROE is -0.55%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, IOVA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MDGL's competition here
IOVA vs IONS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, IOVA is priced at $3.35, while IONS trades at $73.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas IONS's P/E ratio is -31.42. In terms of profitability, IOVA's ROE is -0.55%, compared to IONS's ROE of -0.69%. Regarding short-term risk, IOVA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check IONS's competition here
IOVA vs EXEL Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, IOVA is priced at $3.35, while EXEL trades at $43.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas EXEL's P/E ratio is 15.78. In terms of profitability, IOVA's ROE is -0.55%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, IOVA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check EXEL's competition here
IOVA vs JAZZ Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, JAZZ has a market cap of 11.5B. Regarding current trading prices, IOVA is priced at $3.35, while JAZZ trades at $186.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas JAZZ's P/E ratio is -32.01. In terms of profitability, IOVA's ROE is -0.55%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, IOVA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check JAZZ's competition here
IOVA vs RNAM Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IOVA is priced at $3.35, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IOVA's ROE is -0.55%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IOVA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RNAM's competition here
IOVA vs BMRN Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, BMRN has a market cap of 10.7B. Regarding current trading prices, IOVA is priced at $3.35, while BMRN trades at $56.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas BMRN's P/E ratio is 30.83. In terms of profitability, IOVA's ROE is -0.55%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, IOVA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BMRN's competition here
IOVA vs RXDX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IOVA is priced at $3.35, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IOVA's ROE is -0.55%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IOVA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RXDX's competition here
IOVA vs IMGN Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IOVA is priced at $3.35, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IOVA's ROE is -0.55%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IOVA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check IMGN's competition here
IOVA vs AXSM Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, AXSM has a market cap of 8.6B. Regarding current trading prices, IOVA is priced at $3.35, while AXSM trades at $169.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas AXSM's P/E ratio is -45.79. In terms of profitability, IOVA's ROE is -0.55%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, IOVA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check AXSM's competition here
IOVA vs ARWR Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ARWR has a market cap of 8.5B. Regarding current trading prices, IOVA is priced at $3.35, while ARWR trades at $60.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ARWR's P/E ratio is 38.14. In terms of profitability, IOVA's ROE is -0.55%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, IOVA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ARWR's competition here
IOVA vs PCVX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, IOVA is priced at $3.35, while PCVX trades at $59.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas PCVX's P/E ratio is -10.37. In terms of profitability, IOVA's ROE is -0.55%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, IOVA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check PCVX's competition here
IOVA vs BPMC Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IOVA is priced at $3.35, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IOVA's ROE is -0.55%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, IOVA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BPMC's competition here
IOVA vs TECH Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, IOVA is priced at $3.35, while TECH trades at $53.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas TECH's P/E ratio is 100.25. In terms of profitability, IOVA's ROE is -0.55%, compared to TECH's ROE of +0.04%. Regarding short-term risk, IOVA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check TECH's competition here
IOVA vs CYTK Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, IOVA is priced at $3.35, while CYTK trades at $65.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CYTK's P/E ratio is -10.20. In terms of profitability, IOVA's ROE is -0.55%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, IOVA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CYTK's competition here
IOVA vs CERE Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IOVA is priced at $3.35, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CERE's P/E ratio is -16.47. In terms of profitability, IOVA's ROE is -0.55%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IOVA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CERE's competition here
IOVA vs ABVX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ABVX has a market cap of 7.8B. Regarding current trading prices, IOVA is priced at $3.35, while ABVX trades at $118.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ABVX's P/E ratio is -21.33. In terms of profitability, IOVA's ROE is -0.55%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, IOVA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ABVX's competition here
IOVA vs NUVL Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, IOVA is priced at $3.35, while NUVL trades at $103.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas NUVL's P/E ratio is -18.02. In terms of profitability, IOVA's ROE is -0.55%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, IOVA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check NUVL's competition here
IOVA vs KRYS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, IOVA is priced at $3.35, while KRYS trades at $262.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas KRYS's P/E ratio is 38.09. In terms of profitability, IOVA's ROE is -0.55%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IOVA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check KRYS's competition here
IOVA vs HALO Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, IOVA is priced at $3.35, while HALO trades at $63.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas HALO's P/E ratio is 25.19. In terms of profitability, IOVA's ROE is -0.55%, compared to HALO's ROE of +0.93%. Regarding short-term risk, IOVA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check HALO's competition here
IOVA vs IBRX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, IOVA is priced at $3.35, while IBRX trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas IBRX's P/E ratio is -19.21. In terms of profitability, IOVA's ROE is -0.55%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, IOVA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check IBRX's competition here
IOVA vs MTSR Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IOVA is priced at $3.35, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IOVA's ROE is -0.55%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IOVA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MTSR's competition here
IOVA vs KYMR Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, IOVA is priced at $3.35, while KYMR trades at $85.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas KYMR's P/E ratio is -23.14. In terms of profitability, IOVA's ROE is -0.55%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, IOVA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check KYMR's competition here
IOVA vs MRUS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IOVA is priced at $3.35, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IOVA's ROE is -0.55%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IOVA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MRUS's competition here
IOVA vs ACLX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IOVA is priced at $3.35, while ACLX trades at $114.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ACLX's P/E ratio is -28.20. In terms of profitability, IOVA's ROE is -0.55%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IOVA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ACLX's competition here
IOVA vs BLTE Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, IOVA is priced at $3.35, while BLTE trades at $171.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas BLTE's P/E ratio is -73.53. In terms of profitability, IOVA's ROE is -0.55%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, IOVA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check BLTE's competition here
IOVA vs PTGX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, IOVA is priced at $3.35, while PTGX trades at $102.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas PTGX's P/E ratio is -50.62. In terms of profitability, IOVA's ROE is -0.55%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, IOVA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check PTGX's competition here
IOVA vs RETA Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IOVA is priced at $3.35, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas RETA's P/E ratio is -66.29. In terms of profitability, IOVA's ROE is -0.55%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IOVA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RETA's competition here
IOVA vs PRAX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, PRAX has a market cap of 6.6B. Regarding current trading prices, IOVA is priced at $3.35, while PRAX trades at $307.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas PRAX's P/E ratio is -23.04. In terms of profitability, IOVA's ROE is -0.55%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, IOVA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check PRAX's competition here
IOVA vs RYTM Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, IOVA is priced at $3.35, while RYTM trades at $87.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas RYTM's P/E ratio is -27.75. In terms of profitability, IOVA's ROE is -0.55%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, IOVA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RYTM's competition here
IOVA vs ALKS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ALKS has a market cap of 5.8B. Regarding current trading prices, IOVA is priced at $3.35, while ALKS trades at $34.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ALKS's P/E ratio is 24.36. In terms of profitability, IOVA's ROE is -0.55%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ALKS's competition here
IOVA vs SRRK Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, IOVA is priced at $3.35, while SRRK trades at $48.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas SRRK's P/E ratio is -15.20. In terms of profitability, IOVA's ROE is -0.55%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, IOVA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SRRK's competition here
IOVA vs COGT Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, IOVA is priced at $3.35, while COGT trades at $35.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas COGT's P/E ratio is -16.30. In terms of profitability, IOVA's ROE is -0.55%, compared to COGT's ROE of -1.00%. Regarding short-term risk, IOVA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check COGT's competition here
IOVA vs CGON Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, IOVA is priced at $3.35, while CGON trades at $67.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CGON's P/E ratio is -32.44. In terms of profitability, IOVA's ROE is -0.55%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IOVA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CGON's competition here
IOVA vs CDTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IOVA is priced at $3.35, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IOVA's ROE is -0.55%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IOVA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CDTX's competition here
IOVA vs PTCT Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, IOVA is priced at $3.35, while PTCT trades at $68.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas PTCT's P/E ratio is 7.90. In terms of profitability, IOVA's ROE is -0.55%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, IOVA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check PTCT's competition here
IOVA vs ERAS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $3.35, while ERAS trades at $17.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ERAS's P/E ratio is -40.48. In terms of profitability, IOVA's ROE is -0.55%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, IOVA is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ERAS's competition here
IOVA vs ABCM Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $3.35, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IOVA's ROE is -0.55%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IOVA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ABCM's competition here
IOVA vs ISEE Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $3.35, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IOVA's ROE is -0.55%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IOVA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ISEE's competition here
IOVA vs CAI Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CAI has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $3.35, while CAI trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CAI's P/E ratio is -5.99. In terms of profitability, IOVA's ROE is -0.55%, compared to CAI's ROE of +0.25%. Regarding short-term risk, IOVA is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CAI's competition here
IOVA vs CELC Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CELC has a market cap of 5.4B. Regarding current trading prices, IOVA is priced at $3.35, while CELC trades at $114.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CELC's P/E ratio is -29.72. In terms of profitability, IOVA's ROE is -0.55%, compared to CELC's ROE of -2.03%. Regarding short-term risk, IOVA is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CELC's competition here
IOVA vs TGTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, IOVA is priced at $3.35, while TGTX trades at $34.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas TGTX's P/E ratio is 12.10. In terms of profitability, IOVA's ROE is -0.55%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, IOVA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check TGTX's competition here
IOVA vs FBIOX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, IOVA is priced at $3.35, while FBIOX trades at $25.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas FBIOX's P/E ratio is N/A. In terms of profitability, IOVA's ROE is -0.55%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, IOVA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check FBIOX's competition here
IOVA vs CNTA Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CNTA has a market cap of 5.3B. Regarding current trading prices, IOVA is priced at $3.35, while CNTA trades at $39.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CNTA's P/E ratio is -27.18. In terms of profitability, IOVA's ROE is -0.55%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, IOVA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CNTA's competition here
IOVA vs APLS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, IOVA is priced at $3.35, while APLS trades at $40.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas APLS's P/E ratio is 224.50. In terms of profitability, IOVA's ROE is -0.55%, compared to APLS's ROE of +0.08%. Regarding short-term risk, IOVA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check APLS's competition here
IOVA vs IMVT Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, IMVT has a market cap of 5B. Regarding current trading prices, IOVA is priced at $3.35, while IMVT trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas IMVT's P/E ratio is -9.18. In terms of profitability, IOVA's ROE is -0.55%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, IOVA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check IMVT's competition here
IOVA vs CRSP Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, IOVA is priced at $3.35, while CRSP trades at $49.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CRSP's P/E ratio is -7.65. In terms of profitability, IOVA's ROE is -0.55%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, IOVA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CRSP's competition here
IOVA vs TERN Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, IOVA is priced at $3.35, while TERN trades at $52.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas TERN's P/E ratio is -51.18. In terms of profitability, IOVA's ROE is -0.55%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IOVA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check TERN's competition here
IOVA vs MIRM Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, IOVA is priced at $3.35, while MIRM trades at $96.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas MIRM's P/E ratio is -200.36. In terms of profitability, IOVA's ROE is -0.55%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, IOVA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MIRM's competition here
IOVA vs APGE Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, APGE has a market cap of 4.7B. Regarding current trading prices, IOVA is priced at $3.35, while APGE trades at $84.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas APGE's P/E ratio is -19.99. In terms of profitability, IOVA's ROE is -0.55%, compared to APGE's ROE of -0.37%. Regarding short-term risk, IOVA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check APGE's competition here
IOVA vs FOLD Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $3.35, while FOLD trades at $14.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas FOLD's P/E ratio is -160.44. In terms of profitability, IOVA's ROE is -0.55%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IOVA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check FOLD's competition here
IOVA vs CORT Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CORT has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $3.35, while CORT trades at $41.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CORT's P/E ratio is 51.82. In terms of profitability, IOVA's ROE is -0.55%, compared to CORT's ROE of +0.15%. Regarding short-term risk, IOVA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CORT's competition here
IOVA vs AKRO Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $3.35, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IOVA's ROE is -0.55%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IOVA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check AKRO's competition here
IOVA vs XENE Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $3.35, while XENE trades at $56.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas XENE's P/E ratio is -13.04. In terms of profitability, IOVA's ROE is -0.55%, compared to XENE's ROE of -0.56%. Regarding short-term risk, IOVA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check XENE's competition here
IOVA vs ALPN Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $3.35, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IOVA's ROE is -0.55%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IOVA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ALPN's competition here
IOVA vs OPT Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IOVA is priced at $3.35, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas OPT's P/E ratio is -1.52. In terms of profitability, IOVA's ROE is -0.55%, compared to OPT's ROE of +0.88%. Regarding short-term risk, IOVA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check OPT's competition here
IOVA vs MRTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IOVA is priced at $3.35, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IOVA's ROE is -0.55%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IOVA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MRTX's competition here
IOVA vs VKTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, IOVA is priced at $3.35, while VKTX trades at $34.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas VKTX's P/E ratio is -10.91. In terms of profitability, IOVA's ROE is -0.55%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, IOVA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check VKTX's competition here
IOVA vs LGND Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, LGND has a market cap of 4B. Regarding current trading prices, IOVA is priced at $3.35, while LGND trades at $203.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas LGND's P/E ratio is 32.56. In terms of profitability, IOVA's ROE is -0.55%, compared to LGND's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check LGND's competition here
IOVA vs CRNX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, IOVA is priced at $3.35, while CRNX trades at $37.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CRNX's P/E ratio is -7.52. In terms of profitability, IOVA's ROE is -0.55%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, IOVA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check CRNX's competition here
IOVA vs NAMS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, IOVA is priced at $3.35, while NAMS trades at $33.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas NAMS's P/E ratio is -19.18. In terms of profitability, IOVA's ROE is -0.55%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, IOVA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check NAMS's competition here
IOVA vs ACAD Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, IOVA is priced at $3.35, while ACAD trades at $22.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ACAD's P/E ratio is 9.65. In terms of profitability, IOVA's ROE is -0.55%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, IOVA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ACAD's competition here
IOVA vs RYZB Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IOVA is priced at $3.35, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IOVA's ROE is -0.55%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IOVA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RYZB's competition here
IOVA vs CBAY Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IOVA is priced at $3.35, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IOVA's ROE is -0.55%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IOVA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CBAY's competition here
IOVA vs KNSA Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, IOVA is priced at $3.35, while KNSA trades at $49.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas KNSA's P/E ratio is 65.09. In terms of profitability, IOVA's ROE is -0.55%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, IOVA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check KNSA's competition here
IOVA vs EWTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, IOVA is priced at $3.35, while EWTX trades at $33.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas EWTX's P/E ratio is -20.45. In terms of profitability, IOVA's ROE is -0.55%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, IOVA is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check EWTX's competition here
IOVA vs SWTX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IOVA is priced at $3.35, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IOVA's ROE is -0.55%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, IOVA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SWTX's competition here
IOVA vs LEGN Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, IOVA is priced at $3.35, while LEGN trades at $18.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas LEGN's P/E ratio is -11.81. In terms of profitability, IOVA's ROE is -0.55%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, IOVA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check LEGN's competition here
IOVA vs LQDA Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, IOVA is priced at $3.35, while LQDA trades at $37.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas LQDA's P/E ratio is -47.10. In terms of profitability, IOVA's ROE is -0.55%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, IOVA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check LQDA's competition here
IOVA vs DNTH Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, DNTH has a market cap of 3.3B. Regarding current trading prices, IOVA is priced at $3.35, while DNTH trades at $85.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas DNTH's P/E ratio is -20.48. In terms of profitability, IOVA's ROE is -0.55%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, IOVA is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check DNTH's competition here
IOVA vs DNLI Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, IOVA is priced at $3.35, while DNLI trades at $19.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas DNLI's P/E ratio is -6.95. In terms of profitability, IOVA's ROE is -0.55%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, IOVA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check DNLI's competition here
IOVA vs DYN Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, DYN has a market cap of 3.1B. Regarding current trading prices, IOVA is priced at $3.35, while DYN trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas DYN's P/E ratio is -5.43. In terms of profitability, IOVA's ROE is -0.55%, compared to DYN's ROE of -0.61%. Regarding short-term risk, IOVA is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check DYN's competition here
IOVA vs TLX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, IOVA is priced at $3.35, while TLX trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas TLX's P/E ratio is -456.50. In terms of profitability, IOVA's ROE is -0.55%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IOVA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check TLX's competition here
IOVA vs GPCR Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, IOVA is priced at $3.35, while GPCR trades at $51.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas GPCR's P/E ratio is -22.28. In terms of profitability, IOVA's ROE is -0.55%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, IOVA is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check GPCR's competition here
IOVA vs CPRX Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, IOVA is priced at $3.35, while CPRX trades at $24.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas CPRX's P/E ratio is 14.70. In terms of profitability, IOVA's ROE is -0.55%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IOVA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CPRX's competition here
IOVA vs TARS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, TARS has a market cap of 3B. Regarding current trading prices, IOVA is priced at $3.35, while TARS trades at $70.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas TARS's P/E ratio is -44.10. In terms of profitability, IOVA's ROE is -0.55%, compared to TARS's ROE of -0.20%. Regarding short-term risk, IOVA is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check TARS's competition here
IOVA vs ARQT Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ARQT has a market cap of 2.9B. Regarding current trading prices, IOVA is priced at $3.35, while ARQT trades at $23.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ARQT's P/E ratio is -181.77. In terms of profitability, IOVA's ROE is -0.55%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, IOVA is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ARQT's competition here
IOVA vs VERA Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, IOVA is priced at $3.35, while VERA trades at $40.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas VERA's P/E ratio is -8.77. In terms of profitability, IOVA's ROE is -0.55%, compared to VERA's ROE of -0.60%. Regarding short-term risk, IOVA is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check VERA's competition here
IOVA vs ALMS Comparison April 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.1B. In comparison, ALMS has a market cap of 2.9B. Regarding current trading prices, IOVA is priced at $3.35, while ALMS trades at $21.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.15, whereas ALMS's P/E ratio is -8.17. In terms of profitability, IOVA's ROE is -0.55%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, IOVA is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check ALMS's competition here